Opioid antagonists for smoking cessation

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  David, Sean P ^a   Lancaster, Tim ^b   Stead, Lindsay F ^b   Evins, A Eden ^c   Cahill, Kate ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Massachusetts GeneralHospital ^*  (United States)

Author keywords

Buprenorphine therapeutic use ; Humans; Naloxone therapeutic use ; Naltrexone therapeutic use ; Narcotic antagonists *therapeutic use ; Randomized controlled trials as topic; Smoking *drug therapy ; Smoking cessation *methods

Indexed keywords

BUPRENORPHINE; CARBON MONOXIDE; COTININE; NALOXONE; NALTREXONE; NARPAN; NICOTINE; OPIATE ANTAGONIST; PLACEBO; UNCLASSIFIED DRUG;

CIGARETTE SMOKING; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFICACY; FOLLOW UP; HUMAN; MEDLINE; META ANALYSIS; REVIEW; SMOKING CESSATION; SYSTEMATIC REVIEW; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

EID: 77950150488     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003086.pub2     Document Type: Review

References (61)

1. Boureau 1978 {published data only} Boureau F, Willer JC. Failure of naloxone to modify the anti-tobacco effect of acupuncture [Desintoxication tabagique par l'acupuncture: essai negatif de blocage par la naloxone]. Nouvelle Presse Médicale 1978;7(16):1401.
2. Brauer 1999 {published data only} Brauer LH, Behm FM, Westman EC, Patel P, Rose JE. Naltrexone blockade of nicotine effects in cigarette smokers. Psychopharmacology Berl 1999;143:339-46.
3. Caskey 2001 {published data only} Caskey NH, Olmstead RE, Jarvik ME, Madsen DC, Iwamoto-Schaap PN, Terrace S, et al.The acute effects of low dose naltrexone on ad lib smoking in normal heavy smokers (PO2 77). Society for Research on Nicotine and Tobacco 7th Annual Meeting March 23-23 Seattle Washington. 2001:Abstracts book p106.
4. Covey 1999 {published data only} Covey LS, Glassman AH, Stetner F. Naltrexone effects on shortterm and long-term smoking cessation. Journal of Addictive Diseases 1999;18:31-40.
5. Covey LS, Glassman AH, Stetner F. Naltrexone for smoking cessation. Journal of Addictive Diseases 1996;15:147.
6. Epstein 2004 {published data only} * Epstein AM, .King AC. Naltrexone attenuates acute cigarette smoking behavior. Pharmacology, Biochemistry & Behavior 2004;77: 29-37.
7. Epstein AM, King AC. Naltrexone attenuates behavioral and objective measures of cigarette smoking (POS1-29). Society for Research on Nicotine and Tobacco 9th Annual Meeting February 19-22 New Orleans, Louisiana. 2003:Abstracts book p43.
8. Gorelick 1988 {published data only} Gorelick DA, Rose JE, Jarvik ME. Effect of naloxone on cigarette smoking. Journal of Substance Abuse 1988;1:153-9.
9. Houtsmuller 1997 {published data only} Houtsmuller EJ, Clemmey PA, Sigler LA, Stitzer ML. Effects of naltrexone on smoking and abstinence (In: Problems of Drug Dependence 1996, Proceedings of the 58th annual Conference). Nida Research Monograph 1997;174:68.
10. Hutchison 1999 {published data only} Hutchison KE, Monti PM, Rohsenow DJ, Swift RM, Colby SM, Gnys M, et al.Effects of naltrexone with nicotine replacement on smoking cue reactivity: preliminary results. Psychopharmacology Berl 1999;142:139-43.
11. Karras 1980 {published data only} Karras A, Kane JM. Naloxone reduces cigarette smoking. Life Sciences 1980;27:1541-5.
12. King 2000 {published data only} King AC, Meyer PJ. Naltrexone alteration of acute smoking response in nicotine- dependent subjects. Pharmacology, Biochemistry and Behavior 2000;66(3):563-72.
13. King 2006 {published data only} King A, Chilton E, Niaura R, Hatsukami D. Efficacy of naltrexone in smoking cessation: effects of gender on clinical response (PA8-6). Society for Research on Nicotine and Tobacco 9th Annual Meeting February 19-22 New Orleans, Louisiana. 2003:32.
14. * King A, de Wit H, Riley RC, Cao D, Niaura R, Hatsukami D. Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine & Tobacco Research 2006;8:671-82.
15. King AC, Chilton E, Niaura R. Role of naltrexone in initial smoking cessation: preliminary findings. Alcoholism, Clinical and Experimental Research 2002;26(12):1942-4.
16. Knott 2007 {published data only} Knott VJ, Fisher DJ. Naltrexone alteration of the nicotine-induced EEG and mood activation in tobacco-deprived cigarette smokers. Experimental and Clinical Psychopharmacology 2007;15(4):368-81.
17. Krishnan-Sarin 1999 {published data only} Krishnan-Sarin S, Rosen MI, O'Malley SS. Naloxone challenge in smokers. Preliminary evidence of an opioid component in nicotine dependence. Archives of General Psychiatry 1999;56(7):663-8.
18. Lee 2005 {published data only} * Lee YS, Joe KH, Sohn IK, Na C, Kee BS, Chae SL. Changes of smoking behavior and serum adrenocorticotropic hormone, cortisol, prolactin, and endogenous opioids levels in nicotine dependence after naltrexone treatment. Progress in Neuropsychopharmacol and Biological Psychiatry 2005;29(5):639-47.
19. Na C, Ku YS, Lee YS. Smoking Behavior and Hormonal Change After Naltrexone in Nicotine Dependence. 156th Annual Meeting of the American Psychiatric Association, May 17 22, San Francisco CA. 2003:NR694.
20. Mello 1985 {published data only} Mello NK, Lukas SE, Mendelson JH. Buprenorphine effects on cigarette smoking. Psychopharmacology Berl 1985;86(4):417-25. [: PMID 3929312]
21. Mutschler 2002 {published data only} Mutschler NH, Stephen BJ, Teoh SK, Mendelson JH, Mello NK. An inpatient study of the effects of buprenorphine on cigarette smoking in men concurrently dependent on cocaine and opioids. Nicotine & Tobacco Research 2002;4(2):223-8.
22. Nemeth-Coslett 1986 {published data only} Nemeth Coslett R, Griffiths RR. Naloxone does not affect cigarette smoking. Psychopharmacology Berl 1986;89(3):261-4.
23. O'Malley 1998 {published data only} O'Malley S, Krishnan-Sarin SS, Meandzija B. Naltrexone in the treatment of nicotine dependence: A preliminary study. Proceedings of the American Psychiatric Association Annual Meeting. 1997.
24. * O'Malley SS, Krishnan-Sarin S, Meandzija B. Naltrexone treatment of nicotine dependence: a preliminary study. Addiction 1998;93(6):918-9.
25. O'Malley 2006 {published data only} * O'Malley SS, Cooney JL, Krishna-Sarin S, Dubin JA, McKee SA, Cooney NL, et al.A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Archives of Internal Medicine 2006;166(6):667-74.
26. Toll BA, Cooney JL, Mckee SA, O'Malley SS, Cooney NL. Correspondence of interactive voice response (IVR) reports of nicotine withdrawal, craving, and negative mood with questionnaire ratings. Nicotine & Tobacco Research 2008;10(6):1057-64.
27. Toll BA, Cooney NL, Mckee SA, O'Malley SS. Do daily interactive voice response reports of smoking behavior correspond with retrospective reports?. Psychology of Addictive Behaviors 2005;19(3): 291-5.
28. Toll BA, Mckee SA, Martin DJ, Jatlow P, O'Malley SS. Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit. Nicotine & Tobacco Research 2007;9(5):597- 605.
29. Walsh Z, Epstein A, Munisamy G, King A. The impact of depressive symptoms on the efficacy of naltrexone in smoking cessation. Journal of Addictive Diseases 2008;27(1):65-72.
30. White MA, Mckee SA, O'Malley SS. Smoke and mirrors: magnified beliefs that cigarette smoking suppresses weight. Addictive Behaviors 2007;32(10):2200-10.
31. Olmstead 2002 {published data only} Olmstead RE, Caskey NH, Madsen DC, Terrace S, Iwamoto-Schaap PN, Griffith TM, et al.The acute effects of low dose naltrexone on ad lib smoking in normal heavy smokers and chippers. Proceedings for the Society of Research on Nicotine and Tobacco 8th Annual Meeting, Savannah GA. 2002.
32. Ray 2006 {published data only} Ray R, Jepson C, Patterson F, Strasser A, Rukstalis M, Perkins K, Lynch KG, O'Malley S, Berrettini WH, Lerman C. Association of OPRM1 A11G variant with the relative reinforcing value of nicotine. Psychopharmacology Berl 2006;188(3):355-363.
33. Ray 2007 {published data only} Ray RA, Miranda R, Kahler CW, Leventhal AM, Monti PM, Swift R, Hutchison KE. Pharmacological effects of naltrexone and intervenous alcohol on craving for cigarettes among light smokers: a pilot study. Psychopharmacology Berl 2007;193(4):449- 56.
34. Rohsenow 2003 {published data only} Rohsenow DJ, Monti PM, Colby SM, Gulliver SB, Swift RM, Abrams DB. Naltrexone treatment for alcoholics: effect on cigarette smoking rates. Nicotine & Tobacco Research 2003;5(2):231-6.
35. Rohsenow 2007 {published data only} Rohsenow DJ, Monti PM, Hutchison KE, Swift RM, MacKinnon SV, Sirota AD, Kaplan GB. High-dose transdermal nicotine and naltrexone: effects on nicotine withdrawal, urges, smoking, and effects of smoking. Experimental and Clinical Psychopharmacology 2007;15(1):81-92.
36. Rukstalis 2005 {published data only} Rukstalis M, Jepson C, Strasser A, Lynch KG, Perkins K, Patterson F, et al.Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Psychopharmacology Berl 2005;180:41-8.
37. Sutherland 1995 {published data only} Sutherland G, Stapleton JA, Russell MA, Feyerabend C. Naltrexone, smoking behaviour and cigarette withdrawal. Psychopharmacology Berl 1995;120(4):418-25.
38. Wewers 1998 {published data only} * Wewers ME, Dhatt R, Tejwani GA. Naltrexone administration affects ad libitum smoking behavior. Psychopharmacology Berl 1998; 140(2):185-90.
39. Wewers ME, Dhatt RK, Tejwani GA. Naltrexone administration influences cigarette smoking behaviour. Nicotine & Tobacco Research 1999;1(1):112-3.
40. Wong 1999 {published data only} Wong GY,Wolter TD, Croghan GA, Croghan IT, Offord KP, Hurt RD. A randomized trial of naltrexone for smoking cessation. Addiction 1999;94(8):1227-37.
41. Ahmadi 2003 {published data only} Ahmadi J, Ashkani H, Ahmadi M, Ahmadi N. Twenty-four week maintenance treatment of cigarette smoking with nicotine gum, clonidine and naltrexone. Journal of Substance Abuse and Treatment 2003;24:251-5.
42. Byars 2005 {published data only} Byars JA, Frost-Pineda K, Jacobs WS, Gold MS. Naltrexone augments the effects of nicotine replacement therapy in female smokers. Journal of Addictive Diseases 2005;24:49-60.
43. Krishnan-Sarin 2003 {published data only} Krishnan-Sarin S, Meandzija B, O'Malley S. Naltrexone and nicotine patch in smoking cessation: a preliminary study. Nicotine & Tobacco Research 2003;5(6): 851-7.
44. O'Malley 1995 {published data only} O'Malley SS, Croop RS, Wroblewski JW, Labriola DF, Volpicelli JR. Naltrexone in the treatment of alcohol dependence: a combined analysis of two trials. Psychiatric Annals 1995;25:681-688.
45. Roozen 2006 {published data only} Roozen HG, Van Beers SE, Weevers HJ, Breteler MH,Willemsen MC, Postmus PE, et al.Effects on smoking cessation: naltrexone combined with a cognitive behavioral treatment based on the community reinforcement approach. Substance Use and Misuse 2006;41(2):45-60.
46. Toll 2008 {published data only} Toll BA, Leary V, We R, Salovey P, Meandzija B, O'Malley SS. A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain. Addictive Behaviors 2008;33 (1):173-179.
47. Croop 2000 {published data only (unpublished sought but not used)} Naltrexone for smoking cessation. Ongoing study Starting date of trial not provided. Contact author for more information.
48. Benowitz 1999 Benowitz NL. Nicotine addiction. Primary Care 1999;26(3):611-31.
49. Blum 1995 Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Comings DE. Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. Pharmacogenetics 1995;5(3):121-41.
50. Corrigall 1991 Corrigall, WA, Coen KM. Opiate antagonists reduce cocaine but not nicotine self-administration. Psychopharmacology Berl 1991;104 (2):167-70.
51. Goodrich 1990 Goodrich PM. Naloxone hydrochloride: a review. American Association of Nurse Anaesthetists Journal 1990;58(1):14- 16.
52. Handbook 2005 Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions 4.2.5 [updated May 2005]. The Cochrane Library. Vol. 3, Chichester, UK: John Wiley & Sons Ltd, 2005.
53. Hughes 2004 Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD000031.pub2]
54. Malin 1993 Malin DH, Lake JR, Carter VA, Cunningham JS, Wilson OB. Naloxone precipitates nicotine abstinence syndrome in the rat. Psychopharmacology 1993;112(2-3):339-42.
55. Malin 1996 Malin DH, Lake JR, Payne MC, Short PE, Carter VA, Cunningham JS, et al.Nicotine alleviation of nicotine abstinence syndrome is naloxone-reversible. Pharmacology, Biochemistry and Behavior 1996;53(1):81-5.
56. Meyer 1984 Meyer MC, Straughn AB, Lo MW, Schary WL, Whitney CC. Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. Journal of Clinical Psychiatry 1984;45(9 Pt 2):15-19.
57. Pomerleau 1983 Pomerleau OF, Fertig JB, Seyler LE, Jaffe J. Neuroendocrine reactivity to nicotine in smokers. Psychopharmacology 1983;82: 530-7.
58. Shiffman 2000 Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, Paty JA, et al.The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology Berl 2000;148:33-40.
59. Volpicelli 1992 Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry 1992;49(11):49.
60. David 2001 David S, Lancaster T, Stead LF. Opioid antagonists for smoking cessation. Cochrane Database of Systematic Reviews 2001, Issue 3. [DOI: 10.1002/14651858.CD003086.pub]
61. David 2003 David S, Lancaster T, Stead LF. Opioid antagonists for smoking cessation. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD003086.pub]